日前,美国联邦贸易委员会(FTC)以反垄断为由阻碍了有“瓣膜之王”之称的心脏瓣膜巨头公司爱德华生命科学对另一家瓣膜创新公司JenaValve Technology的收购,称该交易将潜在削弱治疗心脏瓣膜疾病医疗器械的市场竞争。 FTC表示,爱德华生命科学和JenaValve是目前仅有的两家在美国开展临床试验,使用经导管主动脉瓣置换系统治疗主动脉瓣关闭不全这种心脏疾病的公司。 2024年,爱德华...
Source Link日前,美国联邦贸易委员会(FTC)以反垄断为由阻碍了有“瓣膜之王”之称的心脏瓣膜巨头公司爱德华生命科学对另一家瓣膜创新公司JenaValve Technology的收购,称该交易将潜在削弱治疗心脏瓣膜疾病医疗器械的市场竞争。 FTC表示,爱德华生命科学和JenaValve是目前仅有的两家在美国开展临床试验,使用经导管主动脉瓣置换系统治疗主动脉瓣关闭不全这种心脏疾病的公司。 2024年,爱德华...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.